-
Product Name
Relatlimab reference antibody
- Documents
-
Description
Anti-LAG3 / CD223 Antibody (Relatlimab)
-
Tested applications
ELISA
-
Species reactivity
Human LAG3 / CD223
-
Isotype
IgG4SP
-
Preparation
Recombinant expression and purified from CHO cells.
-
Clonality
Monoclonal
-
Formulation
0.1 M Pro-Ac, 20 mM Arg, pH 5.0
-
Storage instructions
-80°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions; Avoid repeated freeze-thaw cycles.
-
Validations
SDS-PAGE
Anti-LAG3 / CD223 Antibody (relatlimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
SEC-HPLC
The purity of Anti-LAG3 / CD223 Antibody (relatlimab) is 100%, determined by SEC-HPLC.
Bioactivity: ELISA
Immobilized human LAG3 His at 2 ug/mL can bind Anti-LAG3 / CD223 Antibody (relatlimab), EC50=0.02812 ug/mL.
Bioactivity: FACS
Human LAG3 CHO cells were stained with Anti-LAG3 / CD223 Antibody (relatlimab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.5464 ug/mL.
Research in vivo
Relatlimab inhibited the tumor growth of MC38 on Human LAG3 mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 53.8% at 10 mpk at D28.
Related Products / Services
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"